Delamanid
(Redirected from Deltyba)
Delamanid[edit | edit source]
Delamanid is an antibiotic used in the treatment of multidrug-resistant tuberculosis (MDR-TB). It is a member of the nitroimidazole class of drugs and works by inhibiting the synthesis of mycolic acids, which are essential components of the Mycobacterium tuberculosis cell wall.
Mechanism of Action[edit | edit source]
Delamanid exerts its antibacterial effects by targeting the synthesis of mycolic acids, which are long-chain fatty acids found in the cell walls of mycobacteria. By inhibiting the production of these acids, delamanid disrupts the integrity of the bacterial cell wall, leading to cell death. This mechanism is particularly effective against Mycobacterium tuberculosis, the causative agent of tuberculosis.
Clinical Use[edit | edit source]
Delamanid is specifically indicated for the treatment of pulmonary MDR-TB in combination with other antitubercular drugs. It is not used as a monotherapy due to the risk of developing resistance. The drug is administered orally and is typically part of a longer treatment regimen that may last several months.
Side Effects[edit | edit source]
Common side effects of delamanid include nausea, vomiting, and dizziness. More serious side effects can include QT prolongation, which is a measure of delayed heart repolarization that can lead to serious cardiac arrhythmias. Patients on delamanid are often monitored for changes in heart rhythm, especially if they are taking other medications that can affect the heart.
Pharmacokinetics[edit | edit source]
Delamanid is absorbed in the gastrointestinal tract and undergoes extensive metabolism in the liver. It is primarily excreted in the feces. The drug has a half-life of approximately 30 to 38 hours, allowing for once-daily dosing in most treatment regimens.
Development and Approval[edit | edit source]
Delamanid was developed by Otsuka Pharmaceutical Co., Ltd. and received its first regulatory approval in Japan in 2014. It has since been approved in several other countries for the treatment of MDR-TB. The development of delamanid was part of a broader effort to address the growing problem of drug-resistant tuberculosis, which poses a significant public health challenge worldwide.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
